Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Part of paid clinical trials in Augusta, Georgia.

Sponsor
Augusta University
Study ID
NCT04173338
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
  • Pemetrexed — DRUG
    Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.

Study Details

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

Key Dates

Start date
Jan 23, 2020
Status verified
Jun 2022
Primary completion
Mar 28, 2022
Completion
Mar 28, 2022

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib + Pemetrexed
    Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.

Primary Outcome Measure

Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed [ Time Frame: 4 weeks or 28 days assessment. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Augusta University Georgia Cancer CenterAugustaGeorgia30912-

Find similar trials in Augusta, GA

By condition
Lung cancerBladder cancer
By specialty
OncologyLung oncologyLung diseaseUrology
By research site
Augusta University Georgia Cancer Center· Augusta, GA

Related Studies